B cell treatments for multiple sclerosis.
作者信息
McLauchlan D, Robertson N P
机构信息
Institute of Psychological Medicine and Clinical, Neurosciences, Cardiff University, Cardiff, CF14 4XW, UK.
出版信息
J Neurol. 2017 Apr;264(4):814-816. doi: 10.1007/s00415-017-8442-y.
Abstract
摘要
相似文献
1
B cell treatments for multiple sclerosis.
J Neurol. 2017 Apr;264(4):814-816. doi: 10.1007/s00415-017-8442-y.
2
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Brain. 2010 Aug;133(Pt 8):2232-47. doi: 10.1093/brain/awq176. Epub 2010 Jul 21.
3
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.
4
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Sep;23(10):1367-1376. doi: 10.1177/1352458516677589. Epub 2016 Nov 25.
5
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.
Neurology. 2016 Oct 4;87(14):1464-1472. doi: 10.1212/WNL.0000000000003169. Epub 2016 Sep 2.
6
Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
Mult Scler Relat Disord. 2017 Jan;11:18-24. doi: 10.1016/j.msard.2016.11.005. Epub 2016 Nov 13.
7
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
N Engl J Med. 2008 Oct 23;359(17):1786-801. doi: 10.1056/NEJMoa0802670.
8
Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
Clin Neurol Neurosurg. 2020 Oct;197:106203. doi: 10.1016/j.clineuro.2020.106203. Epub 2020 Sep 2.
9
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.
10
Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
Mult Scler. 2019 Dec;25(14):1942-1945. doi: 10.1177/1352458518810261. Epub 2018 Nov 7.
引用本文的文献
1
Signaling pathways and therapeutic perspectives related to environmental factors associated with multiple sclerosis.
J Neurosci Res. 2018 Dec;96(12):1831-1846. doi: 10.1002/jnr.24322. Epub 2018 Sep 11.
Zotero 插件